303 related articles for article (PubMed ID: 25312709)
1. [Cereblon - a new target of therapy in the treatment of multiple myeloma].
Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
[TBL] [Abstract][Full Text] [Related]
2. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
3. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
4. [Discovery of the target for immunomodulatory drugs (IMiDs)].
Ito T; Ando H; Handa H
Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cereblon levels by anti-myeloma agents.
Díaz-Rodríguez E; Pandiella A
Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
[TBL] [Abstract][Full Text] [Related]
6. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
7. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
Ito T; Handa H
Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
[TBL] [Abstract][Full Text] [Related]
8. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
10. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
11. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
12. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
14. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
15. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Borsi E; Mazzocchetti G; Dico AF; Vigliotta I; Martello M; Poletti A; Solli V; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Rizzello I; Cavo M; Terragna C
Clin Exp Med; 2023 Dec; 23(8):5227-5239. PubMed ID: 37815734
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
[TBL] [Abstract][Full Text] [Related]
17. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
18. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
Gandhi AK; Mendy D; Waldman M; Chen G; Rychak E; Miller K; Gaidarova S; Ren Y; Wang M; Breider M; Carmel G; Mahmoudi A; Jackson P; Abbasian M; Cathers BE; Schafer PH; Daniel TO; Lopez-Girona A; Thakurta A; Chopra R
Br J Haematol; 2014 Jan; 164(2):233-44. PubMed ID: 24206017
[TBL] [Abstract][Full Text] [Related]
19. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
20. [Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review].
An R; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1888-1891. PubMed ID: 28024514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
